Byron J. Hoogwerf - Concepedia

Author

Byron J. Hoogwerf

Also Known As

B HOOGWERF, B Hoogwerf, B J Hoogwerf, B. Hoogwerf, B. J Hoogwerf, B. J. HOOGWERF, B. J. Hoogwerf, B. Kim, B.J. Hoogwerf, BYRON J. HOOGWERF

231

Publications

12.3K

Citations

H-Index

129

Concepts

All Affiliations

Cleveland Clinic Eli Lilly (United States)University of Minnesota Montreal Heart Institute Maryland Medical Research Institute

About

Byron J. Hoogwerf is an author at Cleveland Clinic specializing in medicine, diabetes, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	7	7	700
2	Arts	1	1	87
3	Education	1	1	87
4	Engineering	1	1	48
5	Management	1	1	87

Byron J. Hoogwerf

Publications

9.4K

Citations

H-Index

Page 1

	Year	Citations
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Faramarz Ismail‐Beigi, Timothy E. Craven, Mary Ann Banerji, The Lancet Metabolic SyndromeDiabetes ManagementHealth PolicyCardiovascular DiseaseDiabetes	2010	1.4K
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study John B. Buse, Michael A. Nauck, Thomas Först, The Lancet Diabetes ManagementDiabetesType 2PharmacotherapyDiabetes Mellitus	2012	559
Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Rodica Pop‐Busui, Gregory W. Evans, Hertzel C. Gerstein, Diabetes Care	2010	526
Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes John B. Buse, Richard M. Bergenstal, Leonard C. Glass, Annals of Internal Medicine	2011	503
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes Bernard Zinman, Byron J. Hoogwerf, Santiago Durán García, Annals of Internal Medicine	2007	428
Postprandial Glucose and Insulin Responses to Meals Containing Different Carbohydrates in Normal and Diabetic Subjects John P. Bantle, D C Laine, G. Castle, New England Journal of Medicine NutritionHealthy SubjectsDietary FibreType IiObesity	1983	306
Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial Genell L. Knatterud, Yves Rosenberg, Lucien Campeau, Circulation	2000	274
Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies Jennie H. Best, Byron J. Hoogwerf, William H. Herman, Diabetes Care	2010	252
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes Michaëla Diamant, Michael A. Nauck, Rimma M. Shaginian, Diabetes Care	2014	220
Neuroglycopenic and other symptoms in patients with insulinomas Ana Marie Dizon, Stephan Kowalyk, Byron J. Hoogwerf The American Journal of Medicine Other SymptomsInsulin ManagementDiabetesNeurologyDiabetes Mellitus	1999	205

Page 1